SELECTED PUBLICATIONS

2007 -

Nieminen A, Partanen J, Hau A, Klefstrom J: c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J, 26, 1444-1455, 2007.
IF (06): 10.09

Partanen J, Nieminen A, Makela T, Klefstrom J: Suppression of oncogenic properties of c-Myc by Lkb1 controlled epithelial organization, PNAS, 104, 14694-14699, 2007
IF (06): 9.64

Nieminen AI, Partanen JI, Klefstrom J.: c-Myc blazing a Trail of death: Coupling of the mitochondrial and death receptor pathways by c-Myc. Cell Cycle (invited review), 6:2464-2472, 2007. IF (06): 3.21

Partanen JI, Nieminen A, Klefström, J: 3D view to tumor suppression: Lkb1, epithelial organization, and the arrest of oncogenic c-Myc. Cell Cycle (invited review), 8:716-724, 2009.

1994 - 2006

Verschuren EW, Klefstrom J, Evan GI, Jones N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo.
Cancer Cell. 2, 229-241, 2002.
IF (06): 24.08, Cited (05/07): 40

Klefstrom J, Verschuren EW, Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway.
J Biol Chem. 277, 43224-43232, 2002.
IF (06): 5.81, Cited (05/07): 23

Klefstrom, J.,  Kovanen, P.,  Somersalo, K., Littlewood, T., Evan, G., Saksela, E., Timonen, T., and Alitalo, K.: c-Myc and E1A promote target cell cytolysis by natural killer cells by acting after the exocytotic phase. Oncogene 18, 2181-2188, 1999
IF (05): 6.87, Cited (05/07): 9

Klefstrom*, J., Arighi*, E., Littlewood, T., Jäättelä, M., Saksela, E., Evan, G., and Alitalo, K.: Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kB activation. EMBO J 16, 7382-7392, 1997.
IF (05): 10.05, Cited (05/07): 76

Klefstrom, J., Västrik, I., Saksela, E., Valle, J., Eilers, M., Alitalo, K.: c-Myc induces cellular susceptibility to the cytotoxic action of TNF-a EMBO J 13, 5442-5450, 1994.
IF (05): 10.05, Cited (05/07): 108